Nirmatrelvir for acute COVID-19 to prevent long COVID (PANORAMIC Norway): a double-blind, randomised, placebo-controlled trial

Study limitation reported by the research below: “The level-of-evidence rating of 2 reflects the RCT design, but the premature termination and small sample meaningfully reduce confidence in the estimate.”